GO:0019626 short-chain fatty acid catabolic process: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019626 describes the biological process that breaks down short-chain fatty acids (SCFAs), defined as fatty acids with fewer than six carbons.
• SCFAs such as acetate, propionate, and butyrate are produced by gut microbiota and are central to host energy metabolism, immune regulation, and epigenetic programming.
• Catabolism of SCFAs involves mitochondrial beta-oxidation, transport across membranes, and conversion into acetyl-CoA, propionyl-CoA, and other intermediates.
• SCFA catabolic pathways influence histone acetylation, acylation of proteins, and cellular signaling, linking diet and microbiota to host physiology.
• Dysregulation of SCFA catabolism is associated with cardiovascular disease, metabolic disorders, immune dysfunction, and cancer.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal testing of genes involved in SCFA catabolism and their disease relevance.
Description
Short-chain fatty acids (SCFAs) are aliphatic carboxylic acids with fewer than six carbon atoms, such as acetate, propionate, and butyrate, produced primarily by microbial fermentation of dietary fiber in the gut. The Gene Ontology term GO:0019626, short-chain fatty acid catabolic process, describes the chemical reactions and pathways that result in the breakdown of these molecules. This process is fundamental to host-microbe symbiosis, as SCFAs serve as energy substrates, signaling molecules, and regulators of gene expression. Understanding SCFA catabolism is therefore critical for researchers studying metabolism, immunology, and disease mechanisms. The catabolic process encompasses membrane transport, intracellular activation, and mitochondrial beta-oxidation of SCFAs, leading to the production of acetyl-CoA, propionyl-CoA, and reducing equivalents. These intermediates feed into the tricarboxylic acid cycle and contribute to ATP generation, while also influencing epigenetic marks through histone acetylation and protein acylation. The balance between SCFA production and catabolism shapes host physiology, and its disruption has been linked to cardiovascular, metabolic, and inflammatory diseases. For researchers, GO:0019626 provides a framework to investigate how genetic and environmental factors control SCFA breakdown and how this process can be targeted therapeutically. This article integrates authoritative GO annotations with published literature to outline the mechanisms, key genes, and experimental approaches for studying short-chain fatty acid catabolism.
short-chain fatty acid catabolic process At A Glance
| GO ID | GO:0019626 |
|---|---|
| GO term | short-chain fatty acid catabolic process |
| Ontology | biological_process |
| Synonym | short-chain fatty acid breakdown; short-chain fatty acid catabolism; short-chain fatty acid degradation |
| Definition | The chemical reactions and pathways resulting in the breakdown of a short-chain fatty acid. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons. |
| Major function | Degradation of SCFAs to generate energy and metabolic intermediates, influencing epigenetic and signaling pathways. |
| Related processes | Fatty acid beta-oxidation, acetyl-CoA metabolism, histone acetylation, protein acylation. |
| Key substrates | Acetate, propionate, butyrate, and other SCFAs with fewer than six carbons. |
| Cellular location | Mitochondria and cytoplasm, with transport across plasma and mitochondrial membranes. |
What Is GO:0019626?
GO:0019626, short-chain fatty acid catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of a short-chain fatty acid, which is a fatty acid with an aliphatic tail containing fewer than six carbons. This process includes the transport, activation, and oxidative degradation of SCFAs such as acetate, propionate, and butyrate, ultimately yielding metabolic intermediates that enter central carbon metabolism.
Why Is short-chain fatty acid catabolic process Important in Cell Biology?
Short-chain fatty acid catabolism is a central node connecting diet, gut microbiota, and host physiology. SCFAs derived from microbial fermentation are not only energy sources but also potent regulators of immune function, inflammation, and gene expression. The catabolic process determines the availability of SCFAs for signaling and epigenetic modification, thereby impacting diseases ranging from cardiovascular disorders to cancer and neurological conditions. Understanding GO:0019626 is therefore essential for developing microbiota-targeted therapies and for interpreting how genetic variation in catabolic enzymes affects health.
• SCFA catabolism provides energy substrates for colonocytes and other tissues, supporting gut homeostasis.
• It regulates histone acetylation and protein acylation, linking metabolism to epigenetic programming.
• Dysregulation is implicated in cardiovascular diseases, including heart failure and atherosclerosis.
• SCFA catabolic intermediates influence immune cell memory and function, as shown for CD8+ T cells.
• Altered SCFA metabolism is associated with breast cancer invasiveness and other cancers.
• The process is a therapeutic target in metabolic, immune, and neurological diseases.
• It modulates inflammatory responses in sepsis through protein modification.
• Genetic models of catabolic enzymes help dissect causal roles in disease.
• Microbiota-derived SCFAs and their catabolism affect host epigenetic programming across tissues.
• Understanding SCFA catabolism aids in designing probiotics and dietary interventions.
What Happens During short-chain fatty acid catabolic process?
Uptake and Transport of SCFAs
In simple terms: SCFAs are taken up from the gut into cells and moved to where they are broken down.
Short-chain fatty acids produced by gut microbiota are absorbed by host cells through specific transporters and diffusion mechanisms. Transporters such as MCT1 (SLC16A1) and SMCT1 (SLC5A8) mediate the uptake of acetate, propionate, and butyrate into colonocytes and other cell types. Once inside the cell, SCFAs can be activated to their corresponding acyl-CoA derivatives, a step required for further catabolism. This transport and activation phase ensures that SCFAs are available for mitochondrial oxidation or other metabolic fates.
Mitochondrial Beta-Oxidation of SCFAs
In simple terms: Inside mitochondria, SCFAs are chopped into smaller units to release energy.
Short-chain fatty acids undergo beta-oxidation in mitochondria, although the enzymes involved differ from those for long-chain fatty acids. Butyrate, for example, is converted to butyryl-CoA and then oxidized to acetyl-CoA, which enters the TCA cycle. Propionate is metabolized via propionyl-CoA to succinyl-CoA, a TCA cycle intermediate. Acetate can be directly converted to acetyl-CoA by acetyl-CoA synthetase. These reactions generate reducing equivalents (NADH, FADH2) that drive oxidative phosphorylation and ATP production.
Production of Metabolic Intermediates
In simple terms: The breakdown of SCFAs produces molecules that feed into other metabolic pathways.
Catabolism of SCFAs yields acetyl-CoA, propionyl-CoA, and succinyl-CoA, which are central to energy metabolism and biosynthesis. Acetyl-CoA is a key substrate for the TCA cycle and for acetylation reactions that modify histones and other proteins. Propionyl-CoA can be carboxylated to methylmalonyl-CoA and then isomerized to succinyl-CoA, linking SCFA catabolism to gluconeogenesis and amino acid metabolism. These intermediates also influence signaling pathways and gene expression.
Regulation by Substrate Availability and Microbiota
In simple terms: How much SCFA is broken down depends on diet, gut bacteria, and cellular needs.
The rate of SCFA catabolism is influenced by the composition of the gut microbiota, dietary fiber intake, and host metabolic state. Microbial fermentation produces SCFAs, and their subsequent catabolism in host tissues is regulated by enzyme expression and substrate availability. For instance, butyrate is preferentially oxidized by colonocytes, while acetate and propionate enter the circulation and are metabolized in liver and muscle. This interplay between microbiota and host catabolism shapes systemic SCFA levels and their biological effects.
Integration with Epigenetic and Signaling Pathways
In simple terms: SCFA breakdown products can modify DNA packaging and cell signals.
SCFA catabolism is tightly linked to epigenetic regulation because intermediates such as acetyl-CoA and butyryl-CoA serve as substrates for histone acetyltransferases and other modifying enzymes. Butyrate itself can inhibit histone deacetylases, but its catabolism also affects the availability of acetyl-CoA for acetylation. Additionally, SCFAs and their catabolic derivatives can activate G-protein-coupled receptors (e.g., GPR41, GPR43) that modulate immune and inflammatory responses. Thus, the catabolic process integrates metabolic, epigenetic, and signaling outputs.
Key Genes Involved in GO:0019626 short-chain fatty acid catabolic process
The following genes and proteins are experimentally implicated in short-chain fatty acid catabolism, transport, and related signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACSS2 | Converts acetate to acetyl-CoA for catabolism and acetylation | Links SCFA catabolism to histone acetylation and cancer metabolism |
| ACAT1 | Catalyzes conversion of acetoacetyl-CoA to acetyl-CoA in beta-oxidation | Involved in butyrate and acetate catabolism |
| HADHA | Subunit of mitochondrial trifunctional protein for fatty acid oxidation | Required for short-chain fatty acid beta-oxidation |
| HADHB | Beta-ketothiolase subunit of trifunctional protein | Supports mitochondrial SCFA oxidation |
| SLC16A1 (MCT1) | Monocarboxylate transporter for SCFA uptake | Regulates cellular SCFA availability |
| SLC5A8 (SMCT1) | Sodium-coupled monocarboxylate transporter | Mediates butyrate and propionate transport |
| PPARA | Nuclear receptor regulating fatty acid oxidation genes | Controls expression of catabolic enzymes |
| PPARD | Nuclear receptor promoting fatty acid catabolism | Modulates SCFA oxidation in tissues |
| GPR41 (FFAR3) | SCFA receptor signaling | Mediates immune and metabolic effects of SCFAs |
| GPR43 (FFAR2) | SCFA receptor signaling | Influences inflammation and cancer cell invasion |
| HDAC1 | Histone deacetylase inhibited by butyrate | Links SCFA catabolism to epigenetic regulation |
| HDAC3 | Histone deacetylase affected by SCFA metabolites | Modulates gene expression in response to SCFAs |
| EP300 | Histone acetyltransferase using acetyl-CoA | Integrates SCFA catabolism with transcription |
| CREBBP | Histone acetyltransferase using acetyl-CoA | Epigenetic effector of SCFA metabolism |
| TGFB1 | Cytokine modulated by butyrate | Mediates butyrate effects in heart failure |
| MAPK1 | Kinase in signaling pathways affected by SCFAs | Links SCFA catabolism to MAPK signaling |
| NFKB1 | Transcription factor regulated by SCFAs | Mediates inflammatory responses |
How Is short-chain fatty acid catabolic process Regulated?
Short-chain fatty acid catabolism is regulated at multiple levels, including substrate availability from gut microbiota, expression of transporters and catabolic enzymes, and hormonal signals. Nuclear receptors such as PPARA and PPARD control the transcription of genes involved in fatty acid oxidation, thereby adjusting catabolic capacity to energy demand. SCFA levels themselves can influence signaling through G-protein-coupled receptors (GPR41, GPR43), which modulate immune and metabolic pathways. Additionally, butyrate and other SCFAs can inhibit histone deacetylases, creating feedback loops that affect gene expression and cellular metabolism. In disease states such as heart failure, butyrate-mediated regulation of TGF-beta1/MAPK pathways has been observed.
short-chain fatty acid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Heart failure | Knockout or overexpression in mouse cardiomyocytes |
| GPR43 (FFAR2) | Breast cancer invasion | Knockout in breast cancer cell lines |
| HDAC1 | Epigenetic regulation in cancer and inflammation | Point mutation or knockout in cell lines |
| ACSS2 | Cancer metabolism and histone acetylation | Knockout or overexpression in cancer cells |
| NFKB1 | Sepsis and inflammatory signaling | Knockout in immune cells |
Cardiovascular Disease
SCFA catabolism and signaling are implicated in cardiovascular diseases, including heart failure and atherosclerosis. Butyrate produced by gut microbiota can alleviate heart failure through the TGF-beta1/MAPK pathway, as shown in a mouse model. SCFA acylation of proteins and histones also affects vascular function and inflammation, contributing to disease pathogenesis.
Cancer
SCFA receptors and catabolic pathways influence cancer cell phenotypes. In breast cancer cells, activation of SCFA receptors inhibits invasive phenotypes, suggesting a protective role for SCFA signaling. Butyrate, a product of SCFA catabolism, can affect histone acetylation and gene expression, with implications for cancer therapy.
Immune and Inflammatory Diseases
SCFAs promote the memory potential of antigen-activated CD8+ T cells, linking SCFA catabolism to adaptive immunity. In sepsis, SCFA metabolites modify proteins and influence inflammatory responses. Dysregulated SCFA catabolism may contribute to chronic inflammation and immune disorders.
Metabolic and Neurological Disorders
SCFA receptors and gut microbiota are therapeutic targets in metabolic and neurological diseases. SCFA catabolism affects energy homeostasis and may influence neuroinflammation and brain function through gut-brain signaling. Diet-microbiota interactions that alter SCFA catabolism can induce global epigenetic programming in host tissues, with potential consequences for metabolic health.
From short-chain fatty acid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ACSS2 affect SCFA catabolism and histone acetylation? | ACSS2 knockout cell line |
| Does butyrate-mediated TGF-beta1 signaling require GPR41? | GPR41 knockout mouse or cell line |
| Can a point mutation in HADHA alter short-chain fatty acid oxidation? | HADHA point-mutation knock-in cells |
| Does overexpression of SLC5A8 increase butyrate uptake and catabolism? | SLC5A8 overexpression cell line |
| What is the role of HDAC1 in SCFA-induced gene expression? | HDAC1 knockout or catalytic-dead knock-in |
| Does microbiota-derived butyrate require host catabolism for immune memory? | Germ-free or antibiotic-treated mouse models with gene knockouts |
How to Study the short-chain fatty acid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS metabolomics | SCFA and acyl-CoA levels | Quantifying catabolic intermediates in cells/tissues |
| 13C-SCFA tracing | Flux through beta-oxidation and TCA cycle | Assessing catabolic activity in vitro and in vivo |
| RNA-seq | Expression of catabolic and transport genes | Transcriptional response to SCFAs or genetic perturbation |
| ChIP-seq (H3K27ac) | Histone acetylation changes | Epigenetic effects of SCFA catabolism |
| Acylation proteomics | Protein lysine acetylation/butyrylation | Identifying SCFA-modified proteins |
| Gnotobiotic mouse models | Microbiota-SCFA-host interactions | Causal testing of microbial SCFA production |
| CRISPR knockout screens | Genes required for SCFA catabolism | Discovery of novel catabolic regulators |
| Seahorse respirometry | Mitochondrial oxidation of SCFAs | Functional assessment of beta-oxidation |
Metabolomics and Flux Analysis
Metabolomics using mass spectrometry can quantify SCFA levels and their catabolic intermediates (e.g., acetyl-CoA, propionyl-CoA) in cells and tissues. Stable isotope tracing with 13C-labeled SCFAs allows flux analysis through beta-oxidation and the TCA cycle, revealing how genetic perturbations affect catabolic rates.
Transcriptomics and Epigenomics
RNA-seq can measure expression of genes involved in SCFA transport and catabolism, while ChIP-seq for histone acetylation (e.g., H3K27ac) assesses epigenetic changes driven by SCFA metabolites. These methods help link catabolic activity to gene expression programs.
Proteomics and Acylation Profiling
Proteomic approaches can identify proteins modified by SCFA-derived acyl groups (e.g., lysine acetylation, butyrylation). Antibodies specific for acylated lysines enable Western blot and immunoprecipitation studies to dissect signaling pathways affected by SCFA catabolism.
Microbial and Gnotobiotic Models
Gnotobiotic mice colonized with defined microbial communities or specific SCFA-producing bacteria (e.g., Bacteroides vulgatus) allow investigation of how microbiota-derived SCFAs are catabolized in vivo. Fecal SCFA measurements and tissue-specific catabolic gene expression can be combined to understand host-microbe interactions.
How CRISPR Can Be Used to Study GO:0019626 short-chain fatty acid catabolic process
Knockout
CRISPR knockout of genes such as ACSS2, HADHA, or SLC16A1 can abolish or reduce SCFA catabolism, enabling researchers to test causal roles in energy production, epigenetic regulation, and disease phenotypes. Knockout cell lines and mouse models are valuable for validating metabolic dependencies.
Point Mutation
Introducing point mutations in catalytic residues of enzymes like ACAT1 or HADHA allows precise dissection of enzymatic activity versus structural roles in SCFA catabolism. Such models can reveal whether specific catabolic steps are required for downstream signaling or acetylation.
Knock-in
Knock-in of tagged versions (e.g., FLAG, HA) of catabolic enzymes or transporters facilitates localization, interaction, and stability studies. Knock-in of disease-associated variants can model how genetic polymorphisms affect SCFA catabolism and disease risk.
Overexpression
Overexpression of SCFA transporters (e.g., SLC5A8) or catabolic enzymes can increase flux through the pathway, helping to determine sufficiency in driving metabolic or epigenetic outcomes. Overexpression models are also useful for testing therapeutic hypotheses in cancer and metabolic disease.
How EDITGENE Supports short-chain fatty acid catabolic process Research
Researchers studying short-chain fatty acid catabolic process-related genes often need to determine whether a candidate gene is causally involved in SCFA breakdown, transport, or downstream signaling. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes implicated in GO:0019626 and its associated diseases.
Contact EDITGENE today to design your custom CRISPR model for short-chain fatty acid catabolic process research.
Frequently Asked Questions About short-chain fatty acid catabolic process
What is GO:0019626 short-chain fatty acid catabolic process?
GO:0019626 is a Gene Ontology biological process term describing the chemical reactions and pathways that break down short-chain fatty acids, which are fatty acids with fewer than six carbons, such as acetate, propionate, and butyrate.
What genes are involved in short-chain fatty acid catabolic process?
Key genes include ACSS2, ACAT1, HADHA, HADHB, SLC16A1, SLC5A8, PPARA, PPARD, GPR41, GPR43, HDAC1, HDAC3, EP300, CREBBP, TGFB1, MAPK1, and NFKB1, based on published studies.
Why is short-chain fatty acid catabolism important for health?
It provides energy, regulates histone acetylation and protein acylation, and influences immune function, inflammation, and cardiovascular health.
How are short-chain fatty acids broken down in cells?
SCFAs are transported into cells, activated to acyl-CoA derivatives, and oxidized in mitochondria via beta-oxidation to produce acetyl-CoA, propionyl-CoA, and succinyl-CoA, which enter central metabolism.
What diseases are linked to short-chain fatty acid catabolism?
Dysregulation is associated with cardiovascular disease, cancer, immune disorders, sepsis, and metabolic/neurological conditions.
Which transporters mediate short-chain fatty acid uptake?
MCT1 (SLC16A1) and SMCT1 (SLC5A8) are key transporters for SCFA uptake into cells.
How does butyrate affect heart failure?
Butyrate, a SCFA, can alleviate heart failure via the TGF-beta1/MAPK pathway, as shown in a mouse model.
Can CRISPR be used to study short-chain fatty acid catabolism?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in SCFA catabolism and their disease relevance.
What methods are used to measure short-chain fatty acid catabolism?
Metabolomics, stable isotope tracing, RNA-seq, ChIP-seq, proteomics, and respirometry are commonly used to assess catabolic flux and downstream effects.
How do SCFAs influence epigenetic programming?
SCFA catabolism produces acetyl-CoA and butyryl-CoA, which are substrates for histone acetyltransferases, and butyrate can inhibit histone deacetylases, thereby altering gene expression.
Conclusion
GO:0019626 short-chain fatty acid catabolic process is a critical biological pathway that connects gut microbiota, energy metabolism, and epigenetic regulation. Its dysregulation is implicated in cardiovascular, metabolic, immune, and neoplastic diseases, making it a compelling target for research and therapeutic intervention. By leveraging CRISPR-based models and multi-omics approaches, researchers can dissect the causal roles of specific genes and translate these insights into new treatments.
References
- 1. Bachem A et al.. 2019. Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8(+) T Cells.. Immunity 51(2):285-297.e5 PMID: 31272808
- 2. Krautkramer KA et al.. 2016. Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues.. Mol Cell 64(5):982-992 PMID: 27889451
- 3. Chen XF et al.. 2020. Short-chain fatty acid, acylation and cardiovascular diseases.. Clin Sci (Lond) 134(6):657-676 PMID: 32219347
- 4. Thirunavukkarasan M et al.. 2017. Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells.. PLoS One 12(10):e0186334 PMID: 29049318
- 5. Du Z et al.. 2026. Bacteroides vulgatus alleviates heart failure via butyric acid-TGF-β1/MAPK pathway.. J Adv Res 84:991-1004 PMID: 41076121
- 6. Ikeda T et al.. 2022. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases.. Pharmacol Ther 239:108273 PMID: 36057320
- 7. Sivaprakasam S et al.. 2017. Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis.. Compr Physiol 8(1):299-314 PMID: 29357130
- 8. Zhang L et al.. 2023. Protein modification by short-chain fatty acid metabolites in sepsis: a comprehensive review.. Front Immunol 14:1171834 PMID: 37869005
